Particle.news
Download on the App Store
3 ARTICLES
·
last mo.

Dupixent Fuels Q2 Revenue Gains for Sanofi and Regeneron with Divergent Profit Results

Robust Dupixent demand lifted partner revenues with Sanofi reporting an EPS miss driven by increased R&D spending.

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid/File Photo
The logo of Sanofi is seen at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France, June 11, 2025. REUTERS/Gonzalo Fuentes/File Photo
Dupixent generated sales of €3.8bn ($4.35bn) for the big pharma company in the quarter, growing 21.1% over the same period in 2024. Credit: nitpicker via Shutterstock.com.

Overview

  • Sanofi’s Q2 Dupixent sales reached €3.8 billion, up 21.1% year-on-year, pushing total net sales to €9.9 billion.
  • Earnings per share at Sanofi rose to €1.59, below analyst forecasts, after R&D investment climbed 17.7% to €1.9 billion.
  • The company has completed 80% of its €5 billion share buyback and raised its 2025 sales growth outlook to the high single digits.
  • Sanofi expanded its pipeline through major 2025 deals for Blueprint Medicines, Vicebio, Dren Bio assets and Vigil Neuroscience.
  • Regeneron posted a 22% jump in Dupixent revenue to $4.34 billion, helping it beat Wall Street estimates for Q2 profit and sales.